View article

The recent pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to worldwide uncertainty about the potential risks to those with autoimmune diseases [1]. Long-term immunosuppression in patients with rheumatic diseases is a major concern. As already known, microbial infections have a more severe and complicated course in immunocompromised patients [2]. However, the clinical course of Coronavirus Disease 2019 (COVID-19) in this high-risk population is still unknown [1]. Systemic Sclerosis (SSc) is a systemic autoimmune disease with multi-organ manifestations secondary to fibrosis and vasculopathy. Cardiopulmonary involvement is a major problem and the main cause of mortality in these patients [3]. Theoretically, the synergistic effect of long-term immunosuppression and underlying pulmonary involvement renders these patients susceptible to a more severe form of …